What does Cruise and Blast mean in a testosterone cycle context?

Cruise and Blast is a long-term cycling strategy where the athlete alternates between a high-dose blast phase — typically 400–600 mg/week — designed to maximise anabolic stimulus, and a low-dose cruise phase at 100–200 mg/week that maintains androgen levels without requiring PCT. The two phases are run back-to-back without a full off-cycle break, using one product throughout.

How long should the cruise phase last before blasting again with NordiTest S?

A cruise phase of four to eight weeks is the most commonly reported range. The midpoint bloodwork panel — measuring total testosterone, haematocrit, and LH — determines readiness to re-enter a blast. Cruise duration is extended if haematocrit remains elevated above 50% or LH has not shown any measurable recovery signal, indicating the HPG axis is still fully suppressed.

At what point during a blast should you switch down to a cruise dose of NordiTest S?

The transition from blast to cruise is typically triggered at week eight to twelve of the blast block, or earlier if bloodwork reveals haematocrit above 52%, LDL:HDL ratio deterioration beyond pre-defined limits, or clinical symptoms such as night sweats and sustained blood pressure elevation. The dose is reduced — not stopped — so the decanoate fraction prevents an abrupt androgenic drop during the transition week.

How do you draw a precise cruise dose from the NordiTest S 10ml vial using an insulin-compatible syringe?

At 300 mg/ml, each 0.1 ml graduation on a standard 1 ml syringe corresponds to 30 mg of testosterone ester blend. A 150 mg cruise dose requires a 0.5 ml draw; a 100 mg dose requires 0.33 ml. Use a fresh drawing needle each time to avoid particulate contamination of the vial septum, then swap to an injection needle before administering.

How should the NordiTest S 10ml vial be stored after first puncture?

Store the opened vial at room temperature (15–25 °C), away from direct light and heat. Refrigeration is not required and may increase oil viscosity, making draws more difficult. The multi-dose vial should be used within 28 days of first puncture; inspect for particulates or cloudiness before each draw and discard if either is present. (2) angle_used

Lab Tested

Nordi Pharma

NordiTest S 300mg/ml 10ml Vial by Nordi Pharma

Name: NordiTest S 300mg/ml 10ml Vial by Nordi Pharma
Brand: Nordi Pharma
SKU: INJ-TMIX-NOR-300-021
Price: 40.00 EUR
Availability: InStock

NordiTest S is a four-ester injectable testosterone blend formulated at 300 mg/ml — a concentration that positions it as a practical anchor compound for structured Cruise & Blast programming, where the athlete alternates between a low-dose maintenance cruise phase and a higher-dose anabolic blast phase within a single ongoing cycle. The graduated ester cascade — spanning rapid-acting propionate through long-acting decanoate — delivers reliable androgenic continuity across both phases without requiring a product switch when moving between protocol stages. Batch release at Nordi Pharma is conditional on passing HPLC potency verification and LAL endotoxin screening before any vial reaches distribution.

€40.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Single vial covers both blast and cruise phases — no product switch required between protocol stages.
300 mg/ml concentration delivers clean 30 mg per 0.1 ml graduation for straightforward phase-specific dose calculation.
Four-ester cascade maintains androgenic continuity through blast-to-cruise transition without acute testosterone drop.
Propionate fraction activates within 48 hours of the first blast injection, confirming rapid phase entry.
Decanoate fraction sustains serum testosterone across the full cruise interval between weekly injections.
HPLC-verified potency and LAL endotoxin clearance on every production lot before release.
10 ml multi-dose vial provides sufficient volume for complete eight-to-twelve-week blast blocks without mid-cycle restocking.

Phase	Dosage	Note
Blast	400–600 mg/week (0.67–1.0 ml per injection, twice weekly)	Run for 8–12 weeks; obtain full bloodwork panel at week 6 and again at blast end before transitioning to cruise
Cruise	100–200 mg/week (0.33–0.67 ml per injection, once or twice weekly)	Maintain for 4–8 weeks; mid-cruise bloodwork (total testosterone, haematocrit, LH) governs re-blast timing
Phase Transition (Blast → Cruise)	Reduce weekly dose by 50% over 1–2 injections	Do not stop abruptly; the decanoate fraction smooths the serum decline during the dose step-down week

Key takeaways

Use NordiTest S at 400–600 mg/week during the blast phase for concentrated androgenic loading.
Scale cruise-phase draws to 0.33–0.5 ml using the 300 mg/ml graduation for precision dosing.
Obtain midpoint bloodwork during each cruise block before re-entering a blast.
Leverage the decanoate fraction to smooth serum levels during blast-to-cruise transitions.
Confirm Lab Tested batch status via HPLC and LAL documentation before administration.

NordiTest S 300mg/ml as a Cruise & Blast Foundation Compound

NordiTest S is a multi-ester testosterone injectable engineered at 300 mg/ml that provides a pharmacokinetically stable androgenic environment suited to Cruise & Blast cycling — the periodisation strategy in which athletes rotate between a suppressive blast phase and a lower-dose cruise phase without returning to baseline or initiating PCT between blocks. The four-ester architecture means a single product serves both phases: the short fractions (propionate, phenylpropionate) maintain responsiveness during phase transitions, while isocaproate and decanoate sustain trough concentrations through the cruise interval. Compared to running separate short- and long-ester products across phases, NordiTest S consolidates the pharmacokinetic range into one vial, reducing injection-volume arithmetic when dose is adjusted downward at cruise entry.

Blast Phase: Dosing and Androgenic Loading

During the blast phase, NordiTest S delivers a concentrated androgenic stimulus. Athletes typically run 400–600 mg per week across two weekly injections, each drawing 0.67–1.0 ml of the 300 mg/ml preparation — a volume that remains manageable for bilateral site rotation. The propionate fraction generates androgenic activity within 48 hours of the opening injection, confirming rapid phase entry without a separate kickstart compound. The decanoate fraction sustains serum testosterone through the full inter-injection interval, preventing the mid-week trough that can blunt anabolic signalling. Blast blocks commonly span eight to twelve weeks before the athlete evaluates bloodwork and transitions to cruise.

Cruise Phase: Maintenance, Suppression Management, and Phase Transition

The cruise phase reduces weekly testosterone intake to physiological-replacement range — typically 100–200 mg per week — with the explicit goal of allowing partial HPG-axis function to stabilise without full PCT. NordiTest S accommodates this by scaling draw volume proportionally: a 150 mg cruise dose requires only a 0.5 ml draw, a precision achievable on a standard 1 ml syringe without estimation error at 300 mg/ml. The decanoate fraction's extended clearance profile means serum testosterone does not crash acutely when weekly dose drops, smoothing the hormonal transition between phases. Cruise duration typically runs four to eight weeks, with bloodwork at the midpoint — measuring total testosterone, haematocrit, and LH — guiding the decision to re-enter blast.

Quality Framework and Lab Verification

Nordi Pharma subjects each NordiTest S production lot to HPLC quantification confirming that total testosterone ester content matches the 300 mg/ml label claim within validated acceptance limits; LAL endotoxin assay results must fall below the pharmacopoeial threshold for parenteral preparations before the lot proceeds to release. These two analytical gates — potency and endotoxin — are the primary quality checkpoints underpinning the Lab Tested designation carried by this product.

Usage

Confirm the NordiTest S vial lot number against the HPLC/LAL batch certificate before drawing your first dose — this verifies the 300 mg/ml label claim has been analytically validated.
Warm the vial briefly between your palms for 30–60 seconds to reduce oil viscosity, particularly when drawing a sub-0.5 ml cruise-phase dose on a 1 ml syringe.
Swab the rubber septum with an alcohol wipe and draw using an 18–21 gauge needle; switch to a 23–25 gauge injection needle before administering to minimise injection-site trauma during the long cruise-phase period.
Rotate injection sites systematically — alternating between glutes, quads, and delts — because cruise-phase protocols extend continuous administration over months, increasing cumulative site load.
Log each injection date, draw volume, and injection site; this record allows accurate calculation of the blast-to-cruise transition point and supports correlation with bloodwork findings.
At the end of each cruise block, schedule a bloodwork panel (total testosterone, LH, FSH, haematocrit, LDL:HDL, liver enzymes) before initiating the next blast — results determine whether blast re-entry is appropriate or whether the cruise phase should be extended.

Warnings

Contraindications: NordiTest S is contraindicated in individuals with androgen-dependent neoplasms, active cardiovascular disease, elevated haematocrit above 54%, or untreated sleep apnoea. Cruise & Blast protocols involve continuous suppression of the HPG axis; this approach is not appropriate for individuals who intend to restore natural testosterone production in the short term.

Side Effects: Sustained androgen exposure across extended Cruise & Blast cycles elevates risk of erythrocytosis, HDL suppression, acne, scalp hair thinning, and testicular atrophy due to prolonged LH/FSH suppression. Estrogen conversion through aromatase may cause water retention and gynaecomastia; the degree correlates with blast-phase dose and individual aromatase activity.

Monitoring: Minimum monitoring schedule for Cruise & Blast: bloodwork at blast week 6, blast end, and cruise midpoint. Panel should include total testosterone, haematocrit, LDL:HDL ratio, liver enzymes (ALT, AST), PSA (men over 40), and LH/FSH. Haematocrit above 52% requires dose reduction or therapeutic phlebotomy before continuing.

PCT: Cruise & Blast protocols do not include traditional PCT between phases. If the athlete ultimately chooses to discontinue entirely, a washout interval of at least 14–18 days following the final injection is required before SERM-based HPG-axis recovery is initiated, accounting for the decanoate fraction's extended clearance.

Frequently asked questions

What does Cruise and Blast mean in a testosterone cycle context?: Cruise and Blast is a long-term cycling strategy where the athlete alternates between a high-dose blast phase — typically 400–600 mg/week — designed to maximise anabolic stimulus, and a low-dose cruise phase at 100–200 mg/week that maintains androgen levels without requiring PCT. The two phases are run back-to-back without a full off-cycle break, using one product throughout.
How long should the cruise phase last before blasting again with NordiTest S?: A cruise phase of four to eight weeks is the most commonly reported range. The midpoint bloodwork panel — measuring total testosterone, haematocrit, and LH — determines readiness to re-enter a blast. Cruise duration is extended if haematocrit remains elevated above 50% or LH has not shown any measurable recovery signal, indicating the HPG axis is still fully suppressed.
At what point during a blast should you switch down to a cruise dose of NordiTest S?: The transition from blast to cruise is typically triggered at week eight to twelve of the blast block, or earlier if bloodwork reveals haematocrit above 52%, LDL:HDL ratio deterioration beyond pre-defined limits, or clinical symptoms such as night sweats and sustained blood pressure elevation. The dose is reduced — not stopped — so the decanoate fraction prevents an abrupt androgenic drop during the transition week.
How do you draw a precise cruise dose from the NordiTest S 10ml vial using an insulin-compatible syringe?: At 300 mg/ml, each 0.1 ml graduation on a standard 1 ml syringe corresponds to 30 mg of testosterone ester blend. A 150 mg cruise dose requires a 0.5 ml draw; a 100 mg dose requires 0.33 ml. Use a fresh drawing needle each time to avoid particulate contamination of the vial septum, then swap to an injection needle before administering.
How should the NordiTest S 10ml vial be stored after first puncture?: Store the opened vial at room temperature (15–25 °C), away from direct light and heat. Refrigeration is not required and may increase oil viscosity, making draws more difficult. The multi-dose vial should be used within 28 days of first puncture; inspect for particulates or cloudiness before each draw and discard if either is present. (2) angle_used

Manufacturer

Nordi Pharma's market standing for NordiTest S rests on a measurable track record in the injectable testosterone category rather than on brand narrative alone: independent testing by third-party analytical laboratories has repeatedly returned potency results consistent with the 300 mg/ml label specification, a consistency that converts into verifiable reputation within communities where lab-testing culture is well established. The brand's positioning within the competitive multi-ester testosterone segment is reinforced by its decision to maintain HPLC and LAL release documentation at the batch level — records that are accessible to purchasers on request — rather than treating analytical compliance as an internal-only quality function. This transparency-first approach distinguishes Nordi Pharma from manufacturers who publish quality claims without accompanying batch-traceable evidence, and it is the specific reputational asset that supports the Lab Tested designation carried by NordiTest S.

Product details

Brand	Nordi Pharma
Active ingredient	testosterone mix
Also known as	Sustanon, Omnadren, Testosterone-Mischung, Sustanon 250, NordiTest S, Nordi Pharma Sustanon
Strength	300 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TMIX-NOR-300-021

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Sustandrol 250mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

GMP Standard

Sustandrol 250mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Sustandrol is a GMP-certified injectable testosterone blend formulated at 250 mg/ml in single-dose 1 ml glass ampoules, manufactured by Balkan Pharmaceuticals at their Chișinău facility under validated pharmaceutical production standards. The four-ester testosterone matrix — propionate, phenylpropionate, isocaproate, and decanoate — delivers a multi-phase serum release profile suited to weekly or bi-weekly injection protocols. Every released batch carries verified analytical documentation: container-closure integrity is confirmed through glass-fusion sealing, potency through HPLC quantification, and endotoxin safety through LAL testing before any unit leaves the production site.

€42.00

High Concentration

Suste-Testosterone 250mg 250mg/ml 10ml Vial by Beligas Pharmaceuticals

Suste-Testosterone 250mg by Beligas Pharmaceuticals is a four-ester testosterone blend formulated at 250mg/ml in a 10ml multi-dose vial, purpose-engineered as the continuous androgenic platform around which advanced multi-compound stacks are architecturally constructed. The staggered ester cascade — spanning rapid-onset propionate through extended-release decanoate — sustains uninterrupted androgenic serum coverage that preserves receptor-priming conditions for every co-administered anabolic throughout the full cycle length. Manufacturing quality is anchored by GMP-certified aseptic filling, per-batch HPLC potency verification, and LAL endotoxin clearance; each released lot carries traceable analytical documentation directly linking the vial to its production record.

€39.00

Verified Manufacturer

Suste-Testosterone 400mg 400mg/ml 10ml Vial by Beligas Pharmaceuticals

Suste-Testosterone 400mg is a high-concentration, oil-based injectable testosterone blend containing four distinct ester fractions — propionate, phenylpropionate, isocaproate, and decanoate — combined at 400mg/ml in a 10ml multi-dose vial, engineered to deliver a continuous androgenic release profile across a wide pharmacokinetic window. Each ester contributes a non-overlapping release phase: the shortest ester activates within 24 hours, while the decanoate component sustains serum testosterone for up to 18–21 days per injection cycle. Quality is locked in at two production stages — raw-material identity confirmed by HPLC against certified reference standards, and finished vials cleared by LAL endotoxin assay before lot release.

€48.00

Susten-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Top Seller

Susten-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Susten-250 is a four-ester testosterone blend formulated at 250 mg/ml by BM Pharmaceuticals, purpose-suited as the anabolic backbone of structured steroid stacks. Its staggered ester release — from propionate's rapid onset through decanoate's sustained tail — gives stack designers the hormonal continuity needed to support both bulking compounds and lean-mass agents across a full cycle. Every production batch is released only after passing HPLC potency verification and LAL endotoxin screening; sterility is confirmed per pharmacopoeial requirements before any ampoule leaves the facility.

€42.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00